Chemoinformaics analysis of CARYOLANE-1,9-BETA-DIOL
| Molecular Weight | 238.371 | nRot | 0 |
| Heavy Atom Molecular Weight | 212.163 | nRig | 14 |
| Exact Molecular Weight | 238.193 | nRing | 3 |
| Solubility: LogS | -3.504 | nHRing | 0 |
| Solubility: LogP | 3.008 | No. of Aliphatic Rings | 3 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 3 |
| Atoms Count | 43 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 17 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 2 | No. Saturated Carbocycles | 3 |
| No. of Hydrogen atom | 26 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 15 | No. of Saturated Rings | 3 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 43.9906 |
| nHD | 2 | BPOL | 26.0834 |
| QED | 0.681 |
| Synth | 5.127 |
| Natural Product Likeliness | 3.137 |
| NR-PPAR-gamma | 0.039 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.013 |
| Pgp-sub | 0.001 |
| HIA | 0.008 |
| CACO-2 | -4.728 |
| MDCK | 0.0000224 |
| BBB | 0.834 |
| PPB | 0.805898 |
| VDSS | 1.189 |
| FU | 0.28298 |
| CYP1A2-inh | 0.027 |
| CYP1A2-sub | 0.366 |
| CYP2c19-inh | 0.039 |
| CYP2c19-sub | 0.852 |
| CYP2c9-inh | 0.104 |
| CYP2c9-sub | 0.788 |
| CYP2d6-inh | 0.01 |
| CYP2d6-sub | 0.624 |
| CYP3a4-inh | 0.179 |
| CYP3a4-sub | 0.162 |
| CL | 14.674 |
| T12 | 0.151 |
| hERG | 0.026 |
| Ames | 0.031 |
| ROA | 0.05 |
| SkinSen | 0.622 |
| Carcinogencity | 0.039 |
| EI | 0.046 |
| Respiratory | 0.498 |
| NR-Aromatase | 0.113 |
| Antiviral | Yes |
| Prediction | 0.884513 |